Pharmacy benefit manager Express Scripts Holding Co.’s commitment that its payer clients will spend no more than $750m collectively on the two new PCSK9 drugs is part of a new drug management approach that also could be applied to other drug classes, according to the firm.
“The cap we are offering each individual client is a novel approach to prescription drug management that we believe will...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?